Immune co-signaling to treat cancer

Margaret K. Callahan, Jedd D. Wolchok, James P Allison, Padmanee Sharma

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Scopus citations

Abstract

The past two decades have been marked by a growing understanding of the co-stimulatory and co-inhibitory pathways that are critical to the generation of an effective, well-regulated immune response. Capitalizing on an increasingly nuanced appreciation for the role that these molecules play in anti-tumor immune responses, a diversity of novel therapies to treat human cancers are being explored. The ground-breaking success of anti-CTLA-4 therapy in the treatment of advanced melanoma has set the stage for the clinical development of agents targeting a diversity of co-stimulatory and co-inhibitory molecules. Herein, we review the co-signaling molecules that regulate T cell activation with a focus on their potential role(s) in anti-tumor immune responses. Where available, pre-clinical and clinical studies evaluating the anti-tumor activity of agents targeting these molecules are presented.

Original languageEnglish (US)
Title of host publicationCancer Immunotherapy
Subtitle of host publicationParadigms, Practice and Promise
PublisherSpringer New York
Pages211-280
Number of pages70
Volume9781461447320
ISBN (Electronic)9781461447320
ISBN (Print)1461447313, 9781461447313
DOIs
StatePublished - May 1 2013

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Callahan, M. K., Wolchok, J. D., Allison, J. P., & Sharma, P. (2013). Immune co-signaling to treat cancer. In Cancer Immunotherapy: Paradigms, Practice and Promise (Vol. 9781461447320, pp. 211-280). Springer New York. https://doi.org/10.1007/978-1-4614-4732-0_8